Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562887 | 1.00 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1562256 | 0.84 | ALDH1A1 (0.35) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL1562258 | 0.84 | ALDH1A1 (0.35) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL3942860 | 0.84 | ALDH1A1 (0.35) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL4248258 | 0.83 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4248261 | 0.83 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4251937 | 0.83 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1562565 | 0.82 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4427707 | 0.82 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4425484 | 0.82 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107438599-B | Targeted Notch pathway inhibitors | 豪夫迈·罗氏有限公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3307721-B1 | TARGETED NOTCH PATHWAY INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-10632127-B2 | Targeted notch pathway inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10632127-B2 | Targeted notch pathway inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180200262-A1 | TARGETED NOTCH PATHWAY INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200262-A1 | TARGETED NOTCH PATHWAY INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3307721-A1 | TARGETED NOTCH PATHWAY INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198366-A1 | TARGETED NOTCH PATHWAY INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016198366-A1 | TARGETED NOTCH PATHWAY INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-15 | — | — | WO | disclosed |
| EP-2109604-A1 | 6-OXO-6,7-DIHYDRO-5H-DIBENZO[B,D]AZEPIN-7-YL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-10-21 | — | — | EP | disclosed |
| EP-2069317-A2 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[B][1,4]DIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-7544679-B2 | 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008092786-A1 | 6-OXO-6,7-DIHYDRO-5H-DIBENZO[B,D]AZEPIN-7-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188463-A1 | 6-OXO-6,7-DIHYDRO-5H-DIBENZO[B,D]AZEPIN-7-YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008034735-A2 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[B][1,4]DIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
| US-10632127-B2 | Targeted notch pathway inhibitors | BACE1, NOTCH1, GSAP | PSEN1 15/4885PSEN2 24/4885APH1B 9/4885 |
| US-20080188463-A1 | 6-OXO-6,7-DIHYDRO-5H-DIBENZO[B,D]AZEPIN-7-YL DERIVATIVES | BACE1, BACE2, APH1B | PSEN1 9/4885PSEN2 13/4885APH1B 3/4885 |
| US-20180200262-A1 | TARGETED NOTCH PATHWAY INHIBITORS | BACE1, NOTCH1, GSAP | PSEN1 15/4885PSEN2 26/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.